AbbVie bets nearly $11bn on a biotech whose drugs aren't proven yet — and it wasn't alone this week

Biotech & Longevity 4 min 80 sources

A wave of pharma dealmaking, led by AbbVie's roughly $11 billion move for Apogee Therapeutics, shows big drugmakers buying promising science years before it's certain to work.

Key takeaways

AbbVie is nearing a roughly $11 billion deal for Apogee Therapeutics, paying a 60% premium for drugs that are still in mid-stage trials and not yet proven.
It was one of at least six biotech deals this week — big drugmakers are buying promising science early, paying today for results that may be years away or may never come.
Neumora's depression drug failing its third trial and triggering layoffs is the reminder of why these are bets: even drugs that reach final testing often fail.

The biggest pharmaceutical companies spent this week shopping — and paying steep prices for drugs that have not yet proven they work in the patients who would take them.

The deal of the week

AbbVie, one of the world’s largest drugmakers, is nearing a deal to buy Apogee Therapeutics for about $10.9 billion in cash [1][2]. Apogee is a small biotech founded in 2022 that develops treatments for inflammatory and immune diseases — conditions like eczema and asthma, where the body’s own defences attack healthy tissue [2].

The striking number isn’t just the size. AbbVie would pay roughly a 60% premium over Apogee’s share price the day before the report — meaning it is paying well above what the market valued the company at [1][2]. And Apogee only raised a separate financing package worth up to $1 billion last month [2], so it was not short of cash. AbbVie wants the science, and it wants it now.

What makes this notable: Apogee’s lead drugs are still in mid-stage trials. They have shown early promise, but they have not yet finished the large, final tests that prove a drug is safe and effective enough to sell. AbbVie is buying a bet, not a finished product.

Why a giant pays up front

There’s a clock behind this. AbbVie’s best-selling drug, the anti-inflammatory Humira, has lost its patent protection, and cheaper copies are eating its sales. Big drugmakers facing that kind of cliff often buy their way to the next generation of medicines rather than wait years to grow them in-house [1].

Apogee’s appeal is that its drugs are designed to be longer-lasting versions of treatments that already work — potentially needing fewer injections [2]. If they pass their final trials, AbbVie owns a ready franchise in a crowded, lucrative market. If they fail, AbbVie has spent $11 billion on a promise. That risk is exactly what the premium pays for: certainty that someone else doesn’t get there first.

It was a buying spree, not a one-off

The Apogee deal sat at the top of a busy week.

Biogen agreed to buy RayThera for up to $1 billion, picking up immune-disease drugs that are still pre-clinical — meaning they haven’t even been tested in humans yet [3].
Jazz Pharmaceuticals and AbCellera struck a discovery partnership worth up to $792 million per drug, aimed at a class of cancer treatments called T-cell engagers — antibodies built to drag the immune system’s killer cells onto a tumour [4].
Merck committed up to $510 million to Protillion to use artificial intelligence in finding new drugs [5][6].
A private-equity firm, Altaris, bought the AI drug-development software maker Simulations Plus for $375 million [7].
Sun Pharma of India agreed to buy Innovcare Lifesciences for about $28.7 million — small by comparison, but part of the same hunt [8].

The pattern is the same at every size: companies paying today for work that won’t pay off for years, if it pays off at all.

The week’s reminder that bets fail

If you want to see why these are bets, look at Neumora. Its depression drug, navacaprant, failed its third late-stage trial in a row [9]. The company is laying off about 35% of its staff [9]. A drug that looked promising enough to take all the way to final testing still couldn’t beat its comparison and crashed the company around it.

That is the shadow side of the dealmaking. For every Apogee that gets bought at a premium, there is a navacaprant that spent years and hundreds of millions reaching the finish line — and lost.

A quieter story worth noting

Away from the deals, one piece of basic science stood out. Researchers reported that developing brain cells appear to break their own DNA on purpose to switch on the genes that build the brain, then repair the breaks afterward [10]. It sounds alarming — deliberately snapping the genetic code — but it may be a normal, controlled step in how a brain wires itself early in life. It is early work, not a treatment, but it is the kind of finding that reshapes how scientists think the brain is assembled.

02 · Lesson · why it matters

What you're really buying when you pay for something that hasn't happened yet

A price isn't a verdict on what a thing is worth today. It's a bet on what it will be worth tomorrow — and the bigger the unknown, the more of the price is pure wager.

A number that looks wrong until you see what it’s for

AbbVie is paying about $11 billion for a company whose drugs haven’t finished proving they work. It’s paying 60% more than the market thought the company was worth a day earlier. On the surface that reads like a mistake — paying extra for something unfinished.

It isn’t a mistake. It’s the whole point. AbbVie isn’t buying a drug. It’s buying the chance that the drug works, and buying it before anyone else can. The 60% isn’t a tip. It’s the price of getting there first, paid in full, today, for an answer that won’t arrive for years.

The thing being sold is a future, not an object

Most of what we buy is finished. A loaf of bread is a loaf of bread. You can see it, hold it, eat it. The price matches the thing.

A drug in mid-stage trials is not like that. There is no finished thing yet — only a strong hint that there might be one. What changes hands isn’t a medicine. It’s a position: the right to own the medicine if it turns out to exist. That’s why the same week saw Biogen pay up to a billion for drugs not yet tested in a single human, and Merck pay half a billion for a company that finds drugs with software. None of these things are real yet. The money is for the odds.

Someone has to hold the risk — and it’s never free

Here’s the part that’s easy to miss. When AbbVie pays a premium, it isn’t being generous. It’s taking the risk off someone else’s hands. Apogee’s investors no longer have to wait and pray the final trials work. They get their money now, with the 60% on top, and AbbVie inherits the gamble.

Risk doesn’t vanish in a deal. It moves. Whoever pays the premium is the one volunteering to be wrong if it goes wrong. That’s what the extra money buys: not certainty, but the right to carry the uncertainty yourself, in exchange for the prize if you’re right.

The losers are in the same picture as the winners

It’s tempting to read the dealmaking as proof that the science is winning. But the same week, Neumora’s depression drug failed its third late-stage trial and the company cut a third of its staff. That drug also looked promising once. Someone also paid for its future. The future didn’t arrive.

You cannot see the Apogees without the Neumoras, because they are the same system. The premiums paid to the winners are funded, in part, by the willingness to lose on the ones that don’t make it. A world that only ever paid for sure things would never pay for any drug at all — because no drug is a sure thing until the trial ends. The losses aren’t a flaw in the system. They’re the price of admission to the wins.

You are already doing this

This is not a story that lives only in boardrooms. You make the same bet constantly, with smaller numbers. The degree you study for a job that might not exist when you finish. The skill you practise now for a payoff years away. The savings you set aside against a future you can’t see. Every one of them is money or time spent on something that hasn’t happened yet — a price paid against odds.

And you sit inside other people’s bets too. The pension fund that owns a slice of Apogee is making this wager on your behalf, whether you chose it or not. When a giant pays $11 billion for an unproven drug, the cost and the hope thread back through markets to ordinary savers an ocean away — people who will never read the deal but quietly hold a piece of its outcome.

The humbling part isn’t that experts pay for uncertain futures. It’s how little any one of them can see of whether they’re right. AbbVie has armies of analysts and still doesn’t know if the drug works — no one does, until it does. The premium is an honest admission dressed as a confident move: we are paying real money to find out something we cannot yet know. When you next pay up for a future of your own, it’s worth holding the certainty a little more loosely. The people with the biggest budgets and the best information are, in the end, doing the same thing you are — guessing, carefully, with money on the line.

03 · Lab · your turn

The Acquisition Desk

Rehearse paying a premium to buy unproven drugs before the trial result is known — and feel that the risk you pay to take never disappears.

04 · Hope · carry this

That so much money chases drugs that might fail is, oddly, a reason for cheer: it means people with everything to lose still bet on medicines that don't exist yet — and every cure we now take for granted was once exactly that kind of unproven bet someone chose to make.